

Julian Weldon Adlard

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3206003/julian-weldon-adlard-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

54
papers

4,330
citations

25
h-index

56
g-index

56
ext. papers

5,677
ext. citations

8
avg, IF

3.74
L-index

#	Paper	IF	Citations
54	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. <i>Genetics in Medicine</i> , 2021 , 23, 1726-1737	8.1	2
53	Multiple primary cancers (renal papillary, lymphoma and teratoma) and hepatic cysts in association with a pathogenic germline mutation in the MET gene. <i>Familial Cancer</i> , 2021 , 20, 81-83	3	1
52	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. <i>Nature Communications</i> , 2021 , 12, 1078	17.4	4
51	Homozygosity for the pathogenic RET hotspot variant p.Cys634Trp: A consanguineous family with MEN2A. <i>European Journal of Medical Genetics</i> , 2021 , 64, 104141	2.6	
50	Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. <i>American Journal of Obstetrics and Gynecology</i> , 2021 , 225, 51.e1-51.e17	6.4	9
49	Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	3
48	Long-read nanopore sequencing enables accurate confirmation of a recurrent PMS2 insertion-deletion variant located in a region of complex genomic architecture. <i>Cancer Genetics</i> , 2021 , 256-257, 122-126	2.3	1
47	SDHC pheochromocytoma and paraganglioma: A UK-wide case series. <i>Clinical Endocrinology</i> , 2021 ,	3.4	2
46	Prostate Cancer Risk by BRCA2 Genomic Regions. <i>European Urology</i> , 2020 , 78, 494-497	10.2	2
45	Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2020 , 22, 8	8.3	22
44	Association of Genomic Domains in and with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020 , 80, 624-638	10.1	22
43	Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study. <i>European Urology</i> , 2020 , 77, 24-35	10.2	53
42	Cancer Risks Associated With Germline Pathogenic Variants: An International Study of 524 Families. <i>Journal of Clinical Oncology</i> , 2020 , 38, 674-685	2.2	133
41	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. <i>Genetics in Medicine</i> , 2020 , 22, 1653-1666	8.1	34
40	Cas9-based enrichment and single-molecule sequencing for precise characterization of genomic duplications. <i>Laboratory Investigation</i> , 2020 , 100, 135-146	5.9	15
39	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. <i>British Journal of Cancer</i> , 2019 , 121, 180-192	8.7	13
38	Additional loss of MSH2 and MSH6 expression in sporadic deficient mismatch repair colorectal cancer due to MLH1 promoter hypermethylation. <i>Journal of Clinical Pathology</i> , 2019 , 72, 443-447	3.9	9

37	Increasing Evidence for the Association of Breast Implant-Associated Anaplastic Large Cell Lymphoma and Li Fraumeni Syndrome. <i>Case Reports in Genetics</i> , 2019 , 2019, 5647940	0.7	10
36	The p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2019 , 5, 38	7.8	12
35	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 350-364	9.7	22
34	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. <i>Human Mutation</i> , 2018 , 39, 593-620	4.7	138
33	Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes , and. <i>Journal of Medical Genetics</i> , 2018 , 55, 384-394	5.8	97
32	Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study. <i>Genetics in Medicine</i> , 2018 , 20, 1575-1582	8.1	12
31	Comprehensive Cancer-Predisposition Gene Testing in an Adult Multiple Primary Tumor Series Shows a Broad Range of Deleterious Variants and Atypical Tumor Phenotypes. <i>American Journal of Human Genetics</i> , 2018 , 103, 3-18	11	27
30	Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 1328-1341	9.7	97
29	Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. <i>JNCI Cancer Spectrum</i> , 2018 , 2, pky023	4.6	13
28	Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 317, 2402-2416	27.4	1140
27	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017 , 49, 680-691	36.3	190
26	Increased Sensitivity of Diagnostic Mutation Detection by Re-analysis Incorporating Local Reassembly of Sequence Reads. <i>Molecular Diagnosis and Therapy</i> , 2017 , 21, 685-692	4.5	3
25	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017 , 49, 1767-1778	36.3	186
24	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2240-2250	2.2	101
23	Characterization and Genomic Localization of a SMAD4 Processed Pseudogene. <i>Journal of Molecular Diagnostics</i> , 2017 , 19, 933-940	5.1	4
22	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. <i>Breast Cancer Research and Treatment</i> , 2017 , 161, 117-134	4.4	15
21	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>PLoS ONE</i> , 2016 , 11, e0158801	3.7	7
20	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , 2016 , 18, 15	8.3	58

19	Histopathology of melanocytic lesions in a family with an inherited BAP1 mutation. <i>Journal of Cutaneous Pathology</i> , 2016 , 43, 287-9	1.7	8
18	Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 1347-61	27.4	286
17	Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. <i>European Urology</i> , 2015 , 68, 186-93	10.2	192
16	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2015 , 17, 61	8.3	16
15	DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. <i>PLoS Genetics</i> , 2014 , 10, e1004256	6	33
14	Robust diagnostic genetic testing using solution capture enrichment and a novel variant-filtering interface. <i>Human Mutation</i> , 2014 , 35, 434-41	4.7	32
13	Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. <i>Breast Cancer Research</i> , 2014 , 16, 3419	8.3	82
12	Lymphocyte telomere length is long in BRCA1 and BRCA2 mutation carriers regardless of cancer-affected status. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 1018-24	4	12
11	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2014 , 16, 3416	8.3	46
10	Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 812-22	9.7	616
9	Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. <i>PLoS Genetics</i> , 2013 , 9, e1003173	6	90
8	Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. <i>PLoS Genetics</i> , 2013 , 9, e1003212	6	209
7	Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2012 , 14, R63	8.3	15
6	A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 1362-70	4	20
5	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , 2011 , 13, R110	8.3	62
4	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. <i>Human Molecular Genetics</i> , 2011 , 20, 3304-21	5.6	62
3	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. <i>Human Molecular Genetics</i> , 2011 , 20, 4732-47	5.6	21
2	MLH1 -93G>A promoter polymorphism and risk of mismatch repair deficient colorectal cancer. <i>International Journal of Cancer</i> , 2008 , 123, 2456-9	7.5	43

1 Thalidomide in the treatment of cancer. *Anti-Cancer Drugs*, **2000**, 11, 787-91

2.4 27